###### Strengths and limitations of this study

-   Although single photon emission computed tomography ventilation/perfusion (SPECT V/Q) has already been largely implemented in daily practice for PE diagnosis, the test is still described as experimental in clinical guidelines.

-   Many studies have been published on SPECT V/Q for pulmonary embolism (PE) diagnosis but the performance of the test is still unclear because of methodological issues.

-   The performances of SPECT V/Q for the diagnosis of PE will be assessed using objective and widely accepted tools for quality assessment.

-   This systematic review and meta-analysis should provide elements of responses to the ongoing debate about the evidence of SPECT V/Q for the diagnosis of acute PE.

Introduction {#s1}
============

Rationale {#s1a}
---------

The diagnosis of pulmonary embolism (PE) remains challenging. Both missed diagnosis and excess diagnosis have undesirable consequences. Undiagnosed PE could be fatal in up to 25% of patients[@R1] while anticoagulant therapy carries a risk of bleeding.[@R2] Moreover, there is a trend towards indefinite duration of anticoagulant therapy after a first episode of PE that was not provoked by a major risk factor.[@R3] A definitive and accurate diagnostic conclusion is therefore required for all patients with suspected PE.

The diagnostic strategy starts with clinical probability assessment and D-dimer testing. In patients with a non-high/unlikely clinical probability but positive D-dimer, and in patients with a high/likely clinical probability, lung imaging is required. CT pulmonary angiography (CTPA) is currently the predominantly used imaging test for PE. The test has been widely validated in diagnostic accuracy and management outcome studies.[@R4] However, CTPA has some limitations, including the use of an iodinated contrast agent, approximatively 5% of inconclusive tests, higher amount of radiation to the breasts compared with alternative tests and an increasing concern regarding a possible overdiagnosis and overtreatment of PE.[@R7]

The alternative for PE diagnosis is lung scintigraphy. Planar ventilation/perfusion (V/Q) scintigraphy is also a well-established test for the diagnosis of PE.[@R9] The accuracy of the test was assessed in the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) study, which is the planar V/Q scan landmark accuracy study versus pulmonary angiography.[@R10] Diagnostic strategies based on planar V/Q scan were then widely validated in large management outcome studies.[@R8]

In recent years, the technology around V/Q scintigraphy has rapidly evolved allowing the introduction of single photon emission computed tomography (SPECT), a new method of scintigraphic acquisition.[@R14] SPECT V/Q has been reported to improve the diagnostic performances of the test and significantly decrease the proportion of non-diagnostic studies.[@R15] The Nuclear Medicine community is mostly enthusiastic and, already back in 2009, the European Association of Nuclear Medicine guidelines for V/Q scintigraphy strongly recommended the use V/Q SPECT over planar for PE diagnosis.[@R17] Consequently, V/Q SPECT has already largely replaced V/Q planar scintigraphy in many nuclear medicine departments. In a survey performed in 2015 among 331 institutions from Australia, Canada and France, more than 2/3 of centres performed SPECT rather than planar images for PE diagnosis.[@R18]

Many accuracy studies aimed at assessing the diagnostic accuracy of SPECT for PE diagnosis. More recently, a few systematic reviews and meta-analyses have been published,[@R19] and concluded that SPECT was superior to planar imaging,[@R19] and superior[@R21] or equal to CTPA.[@R19] However, the clinical community remains much more cautious about the use SPECT V/Q for PE diagnosis. In particular, the specialists in venous thromboembolism (VTE) consistently describe SPECT V/Q as an experimental test rather than as an established imaging modality.[@R7] Indeed, the exact accuracy of the test is still unclear because of methodological issues. For example, in many of available accuracy studies, there is an incorporation bias with the V/Q SPECT result participating in the final diagnostic conclusion. It is important to note that the previously published systematic reviews and meta-analyses on the diagnostic accuracy of SPECT have incorporated these studies with an incorporation bias into the analyses. This represents an important limitation and needs to be encounted for in the interpretation of the pooled results. In addition, there is wide heterogeneity within the studies in terms of reference standard, acquisition protocol and criteria used for interpretation. Finally, although some studies reported on the risk of VTE during follow-up in patients in whom the diagnosis of PE was ruled out on the basis of a negative V/Q SPECT, most did not use a standardised algorithm and additional tests were often performed at the discretion of the physicians. Thus, the clinical outcome of patients investigated with V/Q SPECT remains unclear.

Given this paradoxical situation of a test already largely implemented in daily practice but still described as experimental by clinicians, there is an urgent need to perform a systematic review on the performances of SPECT V/Q for the diagnosis of PE, using objective and widely accepted tools for quality assessment.

Objectives {#s1b}
----------

The primary objective of this systematic review and meta-analysis is to establish the diagnostic accuracy (sensitivity, specificity, likelihood ratios (LRs)) of SPECT V/Q for the diagnosis of acute PE.

The secondary aim is to review the clinical outcomes of patients investigated for suspicion of acute PE with a standardised algorithm based on V/Q SPECT.

Methods {#s2}
=======

This protocol followed the recommendations in the statement on Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P)[@R24] and PRISMA of Diagnostic Test Accuracy (PRISMA-DTA).[@R25] This protocol has been published in the PROSPERO International Prospective Register of Systematic Reviews with registration number CRD42018084095.

Eligibility criteria {#s2a}
--------------------

Studies will be selected according to the criteria outlined below.

### Study designs {#s2a1}

To answer to the primary objective (diagnostic accuracy), we will include diagnostic accuracy studies of \>10 patients.

To answer to the secondary objective (clinical outcome), we will include randomised controlled trials (RCTs) and prospective cohort studies. Studies with other types of designs, including retrospective cohort studies, case--control studies, case series and case reports will be excluded.

### Participants/Interventions {#s2a2}

The study population of interest will include adults (aged 18 years or older) with a suspected acute PE investigated using a SPECT V/Q.

### Comparator {#s2a3}

This study will be non-comparative.

### Outcome {#s2a4}

The primary outcomes will be sensitivity, specificity and positive and negative LRs of V/Q SPECT for the diagnosis of acute PE.

The secondary outcomes will be:The rate of VTE during a 3-month follow-up period in patients left untreated after a negative diagnostic work-up based on SPECT V/Q.The percentage of patients anticoagulated based on a positive V/Q SPECT study among patients assessed with V/Q SPECT for suspected acute PE.

Information sources and search strategy {#s2b}
---------------------------------------

The following databases will be searched during the electronic component of the systematic review: Medline (via OVID), Embase Classic+Embase (via OVID) and Cochrane's Central Register of Controlled Trials. The specific search strategies will be created by a Health Sciences Librarian with expertise in the design of systematic review searching. A search strategy will be developed to define subject headings and keywords for all searches (see online [supplementary appendix 1](#SP1){ref-type="supplementary-material"} for Medline search). After the Medline strategy is finalised, it will be adapted to the syntax of the other databases. There will be no beginning date identified, while the cut-off date will be 19 December 2017. There will be no language exclusion criteria nor any other publication restrictions. Additional references will be sought by hand-searching the bibliographies of relevant articles.
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Study records {#s2c}
-------------

### Data management {#s2c1}

Literature search results will be imported into EndNote, de-duplicated and then uploaded to the Covidence platform ([www.covidence.org](www.covidence.org)) to facilitate collaboration among the reviewers during the study selection process.

### Selection process {#s2c2}

Two reviewers will independently conduct title and abstract screening procedures. Full reports for all titles and abstracts that appear to meet the inclusion criteria or where there is any uncertainty will be obtained. Conflicts in screening will be resolved by consensus or by a third person. Search results and study selection will be illustrated in a PRISMA flow diagram,[@R26] with reasons specified for excluding articles during full-text screening.

### Data collection process {#s2c3}

A structured data extraction form will be developed to facilitate the process of data collection from the studies that have been included in the review. Two reviewers will independently extract all data. Discrepancies between reviewers will be resolved by consensus or by a third person if necessary.

Data items {#s2d}
----------

We will extract:Study information: reference ID, authors, year of publication, journal and publication status.Study characteristics: country, study period, funding, prospective or retrospective, single centre or multicentre.Population characteristics: age, gender, sample size, referral pattern (eg, outpatients, emergency room or inpatients), prevalence of PE, number of participants lost to follow-up.

For accuracy studies:Patient selection: consecutive or random sample, inclusion and exclusion criteria, clinical probability for PE, additional testing including D-dimer, intended use of the index test, clinical setting.Information related to the index test, that is, V/Q SPECT: radiopharmaceuticals, combined CT acquisition, interpretation criteria (positivity thresholds), blinding information, number of readers and resolution of disagreements.Information related to the reference standard: imaging procedures, interpretation method, follow-up.Flow and timing: time interval and any interventions between the index test and reference standard, patients who did not receive the index test and/or reference standard, patients excluded from the 2×2 table.Outcomes to estimate the test accuracy in the form of a cross tabulation of index test with reference standard (2× 2 table) including the number of true positives, false positives, false negatives and true negatives.

For outcome studies:Patient selection: consecutive or random sample, inclusion and exclusion criteria, clinical probability for PE, additional testing including D-dimer.Study design: RCT or prospective cohort study, a priori defined standardised diagnostic strategy to confirm or exclude PE, blind interpretation of the V/Q SPECT, length of follow-up.Information related to V/Q SPECT: radiopharmaceuticals, combined CT acquisition, interpretation criteria (positivity thresholds), interpretation method, number of negative, positive and indeterminate results.Information related to the diagnostic strategy and therapeutic management: additional testing (D-dimer test, compression ultrasound (CUS), CTPA or V/Q planar) performed in addition to the V/Q SPECT.Outcomes: number of patients with a positive and a negative diagnostic work-up with regard to PE diagnosis, number of patients who received anticoagulation, number of patients lost to follow up, number of patients eligible for outcome assessment, that is, patients left untreated after a negative V/Q SPECT with a 3-month follow-up, number of thromboembolism events during the 3-month follow-up period in patients left untreated, number and cause of death.

Outcomes and prioritisation {#s2e}
---------------------------

The primary outcomes will be sensitivity, specificity and negative and positive LRs of V/Q SPECT for the diagnosis of acute PE.

The secondary outcome will be the rate of VTE during a 3-month follow-up period in patients left untreated after a negative diagnostic work-up.

Risk of bias of individual studies {#s2f}
----------------------------------

The methodological quality and risk of bias of eligible studies will be carefully and rigorously assessed. The risk of bias for each study will be ascertained by two reviewers. Results will be compared and disagreements resolved by discussion or, if needed, with the help of a third reviewer.

Quality assessment {#s2g}
------------------

### Diagnostic accuracy {#s2g1}

The Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool will be used to evaluate the risk of bias and concern about applicability of primary diagnostic accuracy studies[@R27] (see [table 1](#T1){ref-type="table"}).

###### 

QUADAS-2 tool to evaluate the risk of bias and concern about applicability of diagnostic accuracy studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Domain                                               Patient selection                                                                                                                          Index test                                                                                               Reference standard                                                                                                      Flow and timing
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Description                                          Describe methods of patient selection: Describe included patients (prior testing, presentation, intended use of index test and setting):   Describe the index test and how it was conducted and interpreted:                                        Describe the reference standard and how it was conducted and interpreted:                                               Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2×2 table (refer to flow diagram): Describe the time interval and any interventions between index test(s) and reference standard:

  Signalling questions\                                Was a consecutive or random sample of patients enrolled?                                                                                   Were the index test results interpreted without knowledge of the results of the reference standard?      Is the reference standard likely to correctly classify the target condition?                                            Was there an appropriate interval between index test(s) and reference standard?
  (yes/no/unclear)                                                                                                                                                                                                                                                                                                                                                                                                                 

  Was a case--control design avoided?                  If a threshold was used, was it prespecified?                                                                                              Were the reference standard results interpreted without knowledge of the results of the index test?      Did all patients receive a reference standard?                                                                          

  Did the study avoid inappropriate exclusions?                                                                                                                                                                                                                                                            Did all patients receive the same reference standard?                                                                   

                                                                                                                                                                                                                                                                                                           Were all patients included in the analysis?                                                                             

  Risk of bias: High/low/unclear                       Could the selection of patients have introduced bias?                                                                                      Could the conduct or interpretation of the index test have introduced bias?                              Could the reference standard, its conduct or its interpretation have introduced bias?                                   Could the patient flow have introduced bias?

  Concerns regarding applicability: High/low/unclear   Are there concerns that the included patients do not match the review question?                                                            Are there concerns that the index test, its conduct or interpretation differ from the review question?   Are there concerns that the target condition as defined by the reference standard does not match the review question?   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We will consider appropriate the following reference standard tests: negative D-dimer in the presence of low or intermediate or unlikely clinical probability, planar V/Q scan when used and interpreted according to well-accepted diagnostic algorithms, CTPA or pulmonary angiography. Special attention will be paid to the independence of the reference standard with regard to the V/Q SPECT results in order to avoid any incorporation bias, and to the blind interpretation of the V/Q SPECT. The description of the reference standard will be considered appropriate if explained with sufficient detail to permit replication of the test. The time between reference standard and index test will be considered acceptable if \<24 hour.

A judgement as to the possible risk of bias and concern about applicability on each item in the domains will be made. The results of the QUADAS-2 assessment for all included studies will be summarised in a table and a graphical display. If the answers to all signalling questions for a domain are 'yes', then the risk of bias and concern regarding applicability will we judged low. If a study is judged 'high' or 'unclear' in one or more domains, then it will be judged 'at risk of bias' or as having 'concerns regarding applicability.'

### Clinical outcomes {#s2g2}

RCTs will be appraised using the Cochrane Collaboration's tool for assessing risk of bias.[@R28] For studies that have used a cohort design, the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool[@R29] for assessing the quality of non-randomised studies in meta-analyses will be used.

Particular attention will be paid to several criteria: (1) prospective enrolment of unselected patients with suspected PE; (2) a standardised PE diagnostic algorithm and management. If performed, the use of additional testing such as D-dimer test, lower-limb venous CUS or CTPA should be standardised and not left at the discretion of the attending physicians. Standardised management is necessary to permit generalisation of results; and (3) reliability of the 3-month follow-up (completeness, description of reasons for incomplete follow-up) and outcome measures (definition at the start of the study, objectivity).

Data synthesis {#s2h}
--------------

### Diagnostic accuracy {#s2h1}

The first step in data synthesis will consist in calculating the descriptive statistics in each primary study. These statistics will include sensitivity, specificity, positive LR and negative LR from the diagnostic 2×2 tables of primary studies. Using the calculated descriptive statistics with the 95% CI of each of the primary studies, a descriptive forest plot will be derived. A summary receiver operating characteristic plot will also be developed.

The main objective of this systematic review is to combine data from primary accuracy studies on V/Q SPECT for the diagnosis of acute PE. Prior to pooling results, the research team will also assess studies for clinical and methodological heterogeneity through comparison of important study characteristics including those related to the study design, patients, V/Q SPECT acquisition and interpretation (positivity threshold). The degree of statistical heterogeneity will be measured and interpreted using a combination of Cochrane's Q (statistically significant at P\<0.10) and the I^2^ statistic (\>50% considered substantial). An I^2^ value \>75% is indicative of a very high degree of heterogeneity and, if encountered, the data will not be pooled. A bivariate random-effects regression approach will be used for summary estimates of both sensitivity and specificity.

### Clinical outcome {#s2h2}

The second objective of this systematic review is to combine data from management outcome studies to assess the safety of a diagnostic strategy based on V/Q SPECT to rule out acute PE. This will be assessed by pooling the rate of VTE event during a 3-month follow-up period in patients left untreated after a negative diagnostic work-up based on SPECT V/Q. Only high-quality studies will be included in the meta analysis, that is, studies with (1) prospective enrolment of unselected patients with suspected PE; (2) an a priori defined PE diagnostic algorithm and management; and (3) a reliable 3-month follow-up and primary outcome measure. Prior to pooling results, the research team will also assess studies for clinical and methodological heterogeneity as described above. If homogeneity among studies is judged as satisfactory, then the results from trials will be pooled using standard meta-analysis procedures.

Patient and public involvement {#s2i}
------------------------------

Patients and public will not be involved in this study since this is a systematic review on published studies.

Discussion {#s3}
==========

In this systematic review and meta-analysis, we aim to assess the diagnostic performance of SPECT V/Q for the diagnosis of acute PE. We decided to assess both diagnostic accuracy of the test and the clinical outcome of patients during follow-up. Studies of new diagnostic tests for PE fall into two broad categories that correspond to early and late stages of test evaluation: accuracy and outcome studies. Accuracy studies determine the accuracy of a new test by comparing the findings with an established 'gold' or reference standard. In such a study, the diagnostic conclusion is based only on the results of the gold standard test. The new test is blindly read, which allows an independent determination of accuracy indices and the assessment of the optimal diagnostic cut-off for quantitative variables. Outcome studies assess the safety and usefulness of the test used the actual diagnostic management of patients. The new test becomes decisional, that is, the diagnostic conclusion and the therapeutic decision are made on the basis of the test's result. The main evaluation criterion is the safety of using the test in deciding patient management and treatment. For VTE diagnosis, a widely accepted criterion is the 3-month rate of VTE in patients left without anticoagulant treatment after a negative strategy. A diagnostic strategy is deemed to safely exclude PE when the 3-month risk is not higher than 3%. This 3% rate corresponds to the upper limit of the 95% CI of VTE rate observed in patients with suspected PE left without anticoagulation after a negative pulmonary angiography.[@R30]

Limitations and challenges {#s3a}
--------------------------

In many available studies, the SPECT V/Q results were provided to the clinicians at the time of the diagnostic work up, and hence participated in the diagnostic conclusion. Therefore, the index test became part of the 'reference standard'. This obviously introduces a major bias and artificially improves the accuracy of the test. Previously published meta-analysis did include such studies in their pooled accuracy indices estimates.[@R19] We will pay particular attention to the independence and blind interpretation between the index test and the reference standard.

Heterogeneity of SPECT V/Q acquisition and interpretation across studies is a potential limitation that can cause challenges to be encountered in this review. According to centres and countries, scanning protocols and interpretation criteria vary. An arising challenge is the increasing use of a combined low-dose CT to enable correlation of functional and anatomical lung abnormalities. The use of a combined CT is thought by some experts to further improve the diagnostic performance of SPECT V/Q. Studies will be carefully examined for the criteria used for interpretation (positivity threshold) and for the exact imaging protocol.

Conclusions {#s4}
===========

Although SPECT V/Q has already been largely implemented in daily practice, the test is still described as experimental by clinicians. In this systematic review and meta-analysis, objective and widely accepted tools will be used to assess studies' quality. Heterogeneity of studies will be assessed using conventional statistical methods. Accordingly, this systematic review and meta-analysis should provide elements of responses to the ongoing debate about the evidence of SPECT V/Q for the diagnosis of acute PE.

Ethics and dissemination {#s5}
========================

Ethical approval and patient consent are not required since this is a systematic review on published studies. The results of this study will be submitted for presentation at relevant national and international conferences, and for publication in a peer-reviewed journal.
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